J&J Settles Talc Suits for $5.5B as Amazon Scales Back AI Models

Johnson and Johnson announced a settlement worth an estimated 5.5 billion dollars to resolve tens of thousands of claims that its talc-based baby powder and other products caused ovarian cancer. The agreement covers roughly 76,000 cases consolidated in federal court in New Jersey along with related state court actions, which together represent nearly all remaining talc claims against the company.

The deal requires approval from 95 percent of the ovarian cancer claimants before it becomes final. Plaintiffs attorneys who helped negotiate the terms described it as a necessary conclusion to years of legal fighting. One lawyer representing about 2,500 clients noted that the resolution brings long-sought accountability after a decade of proceedings.

Johnson and Johnson has long maintained that the claims lack merit and that its products never contained asbestos linked to cancer. The company previously resolved most mesothelioma cases tied to alleged asbestos contamination in talc. Vice president of litigation Erik Haas stated that while the firm believed it would prevail in further trials, the settlement provides closure so the company can focus on developing medicines and devices.

Payments are scheduled to begin with 3 billion dollars in 2027 and additional amounts in 2028, with the total potentially rising if more claimants participate. The litigation has persisted through multiple courtrooms and appeals, drawing attention to internal company documents and scientific debates over talc safety that surfaced during discovery.

Women who used the powder for decades have described diagnoses that upended their lives and left families facing medical costs and loss. Some trials ended with large verdicts against the company before appeals reduced or overturned them. The pattern of settlements and litigation costs has drawn scrutiny to how large corporations manage product liability risks and whether regulators acted quickly enough on emerging concerns.

The agreement does not include an admission of wrongdoing. It follows earlier resolutions on the mesothelioma claims and leaves open questions about how the company will handle any future complaints that fall outside the current terms. Observers note that such large payouts often reflect a calculation that prolonged court battles carry greater financial and reputational risk than negotiated endings.

Johnson and Johnson has emphasized its commitment to safety and innovation while distancing the current consumer health business from past talc operations. The settlement arrives amid broader public skepticism toward pharmaceutical and consumer product giants that have faced repeated accusations of prioritizing profits over transparent risk disclosure.